Clinical application of nateglinide:a Chinese expert consensus
10.3760/cma.j.issn.1000-6699.2011.05.029
- VernacularTitle:那格列奈临床应用中国专家共识
- Author:
Guang NING
;
Lulu CHEN
;
Mingdao CHEN
;
Ping FEN
;
Yan GAO
;
Xiaohui GUO
;
Yanbing LI
;
Juming LU
;
Changyu PAN
;
Haoming TIAN
;
Weiqing WANG
;
Yaoming XUE
;
Li YAN
;
Longyi ZENG
;
Dalong ZHU
;
Dajin ZOU
- Publication Type:Journal Article
- Keywords:
Nateglinide;
Chinese expert concensus;
Diabetes mellitus,type 2
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(5):后插1-后插3
- CountryChina
- Language:Chinese
-
Abstract:
Impaired eady phase insulin secretion is an important reason for leading to postprandial hyperglycemia.Nateglinide is a rapid-acting insulin secretagogue,which reduces postprandial blood glucose of type 2diabetic patient by restoring early phase insulin secretion.The efficacy and safety have been fully verified by clinical administration and it is more widely used to treat type 2 diabetic patients.Both sulfonylureas and glinides were named insulin secretagogue agents and regarded as alternative first-line drugs in the 2010 Chinese Guideline for treatment of type 2 diabetes.AACE/ACE Consensus statement claimed that glinides would be one of the important choices after metformin.In order to further guide the clinical application of nateglinide,16 national specialists in the field of endocrinology and metabolism of China discussed,drafted,and edited this consensus.The current consensus combined clinical evidences at home and abroad.systematically reviewed and summarized tlle results of these studies about nateglinide.It will provide guiding recommendations and reference concerning how to reasonably and effectively use nateglinide in the clinical practice.
